--- title: "Isomorphic Labs' reported $40 billion raise prices Biohub's $1.8 billion cell-data pact" description: "Biohub's virtual-cell commons counts $300 million of new corporate money inside a $1.8 billion headline that leans on federal funds and already-bought assets, and gives commercial partners a one-year exclusive window on the data they fund. That is the substrate under Isomorphic Labs' reported $40 billion ask." publisher: "The Inference" section: "Genomics" published: 2026-10-09T01:25:11.361Z modified: 2026-10-09T01:25:11.361Z canonical: https://theinference.org/article/isomorphic-labs-reported-40-billion-raise-prices-biohub-s-1-8-billion-cell-data-pact language: en keywords: "Isomorphic Labs, Biohub, Google DeepMind, AI Drug Discovery, Virtual Cell, Fundraising" --- # Isomorphic Labs' reported $40 billion raise prices Biohub's $1.8 billion cell-data pact > Biohub's virtual-cell commons counts $300 million of new corporate money inside a $1.8 billion headline that leans on federal funds and already-bought assets, and gives commercial partners a one-year exclusive window on the data they fund. That is the substrate under Isomorphic Labs' reported $40 billion ask. ## Two headlines, one commons On October 7, 2026, Biohub [widened its Virtual Biology Initiative into a $1.8 billion pact](https://bioengineer.org/global-coalition-commits-1-8-billion-to-build-open-data-for-ai-models-of-biology/) with the Department of Energy, the National Institutes of Health, [Google DeepMind](https://theinference.org/markets/companies/google-deepmind), [Isomorphic Labs](https://theinference.org/markets/companies/isomorphic-labs) and [Meta](https://theinference.org/markets/companies/meta), a commitment of funding, data, computing and measurement technology [1]. The next morning, people familiar with the effort said Isomorphic, [Alphabet](https://theinference.org/markets/companies/alphabet)'s DeepMind-spun drug unit, was [in early talks to raise at a valuation of at least $40 billion, as much as $50 billion](https://finance.yahoo.com/healthcare/articles/alphabet-isomorphic-labs-funding-talks-040000989.html) [2]. The second story prices the first. ## What the $1.8 billion actually counts The headline mixes cash with counted assets. Biohub's founding $500 million is a five-year plan, launched April 29 inside the federal Genesis Mission umbrella [1][3]. The DOE pledges more than $500 million over five years for measurement and computing at national labs: exascale supercomputers, X-ray and neutron scattering, cryo-electron microscopy, autonomous laboratories [1][4]. The NIH slice is datasets and repositories from more than $500 million of past federal investment, standardized for training rather than newly bought [1][4]. The new corporate cash, split three ways in undisclosed shares, is $300 million [4][5]. *Chart: **New corporate cash is the smallest slice of the $1.8 billion cell-data effort** Pie chart of the $1.8 billion Virtual Biology Initiative: Biohub $500M five-year plan, DOE $500M over five years, NIH $500M in past-funded resources, and Google DeepMind, Isomorphic Labs and Meta $300M combined.* *Composition of the Virtual Biology Initiative as announced on October 7, 2026; DOE and NIH are 'more than' figures. The NIH slice counts datasets and repositories built with past federal investment, not new outlays. Sources: announcement text [1]; Reuters [4]; Axios [5]. [1][4][5]* ## Twelve months at the gate Commercial partners get [one year of exclusive use of the data they develop before it goes public](https://www.msn.com/en-us/science/general/the-beginning-of-a-new-scientific-paradigm-zuckerberg-s-biohub-us-and-google-build-virtual-cell/ar-AA2dKBCs) [5]. "We have to have some incentive for commercial players to be a part of this, and the embargo period creates that," said Biohub head of science Alex Rives. "But it's a one-year embargo" [5]. Government-funded work in the same effort carries no embargo [4]. Rives expects a first dataset in about a year and accurate predictive models within five [4]. Isomorphic president Max Jaderberg frames the bet as scaling "past the limits of what any single organization can produce" [1]. ## The benchmark still beats the models The field's own scoreboard counsels a discount. In [Arc Institute's 2025 Virtual Cell Challenge](https://xenospectrum.com/en/biohub-virtual-cell-data-initiative/), nearly all entrants scored worse than a simple baseline on mean absolute error, the measure of predicting how large a gene-expression change will be [6]. Organizers watched that metric stop influencing competitors' optimization and added a prize for balance instead [7]. "We're not yet at a point where pure scaling in size can reliably lead to improved outcomes," said Arc investigator Hani Goodarzi [7]. ## The price of a head start Isomorphic [raised a $2.1 billion Series B in May](https://lapaasvoice.com/isomorphic-labs-funding-google-backed-ai-drug-discovery-firm-raises-2-1-billion/), after $600 million in 2025 [8], with Alphabet providing a "large part" of it [2]. [Its first clinical trial is targeted for end-2026, slipped from end-2025](https://theinference.org/article/isomorphic-says-its-ai-is-proven-2-7-billion-rides-on-a-31-december-deadline) [8], in a field where no AI drugmaker has yet brought a medicine to market [2]. Watch the first dataset for which slices arrive embargoed, and whether the 2026 challenge, scored on cell lines models have never seen, humbles the leaders again [6]. On the announced numbers the edge is a lease: twelve months on a commons more than half federally funded. ## Takeaway Only $300 million of Biohub's $1.8 billion Virtual Biology Initiative is new corporate cash, and commercial partners buy a one-year exclusive on the data they fund; Isomorphic's reported ask of $40 billion to $50 billion prices that lease before any AI drugmaker has shipped a medicine. ## Sources 1. [Bioengineer (Scienmag), Global coalition commits $1.8 billion to build open data for AI models of biology, 7 October 2026](https://bioengineer.org/global-coalition-commits-1-8-billion-to-build-open-data-for-ai-models-of-biology/) 2. [Bloomberg via Yahoo Finance, Alphabet's Isomorphic Labs in Funding Talks for at Least $40 Billion Value, 8 October 2026](https://finance.yahoo.com/healthcare/articles/alphabet-isomorphic-labs-funding-talks-040000989.html) 3. [Unite.AI, Biohub, DOE, NIH and Partners Commit $1.8B to Virtual Biology Initiative, 7 October 2026](https://www.unite.ai/biohub-doe-and-nih-invest-1-8b-in-virtual-biology-data-initiative/) 4. [Reuters, US government, Google join Zuckerberg-backed Biohub in $1.8 billion push for AI biology data, 7 October 2026](https://www.msn.com/en-us/money/general/us-government-google-join-zuckerberg-backed-biohub-in-1-8-billion-push-for-ai-biology-data/ar-AA2dL8va) 5. [Axios (Ina Fried), The beginning of a new scientific paradigm: Zuckerberg's Biohub, US and Google build virtual cell, 7 October 2026](https://www.msn.com/en-us/science/general/the-beginning-of-a-new-scientific-paradigm-zuckerberg-s-biohub-us-and-google-build-virtual-cell/ar-AA2dKBCs) 6. [Xenospectrum, Google DeepMind, Meta and US Agencies Join Biohub's $1.8 Billion Virtual Cell Effort, checked 7 October 2026](https://xenospectrum.com/en/biohub-virtual-cell-data-initiative/) 7. [GEN (Fay Lin), NeurIPS 2025: Altos Labs Wins Generalist Prize at Arc's Virtual Cell Challenge, 8 December 2025](https://www.genengnews.com/topics/artificial-intelligence/neurips-2025-altos-labs-wins-generalist-prize-at-arcs-virtual-cell-challenge/) 8. [LapaasVoice, Isomorphic Labs Funding: Google-Backed AI Drug Discovery Firm Raises $2.1 Billion, October 2026](https://lapaasvoice.com/isomorphic-labs-funding-google-backed-ai-drug-discovery-firm-raises-2-1-billion/) --- Isomorphic Labs' reported $40 billion raise prices Biohub's $1.8 billion cell-data pact — The Inference. Canonical: https://theinference.org/article/isomorphic-labs-reported-40-billion-raise-prices-biohub-s-1-8-billion-cell-data-pact